SEC Tracker
Get the app

vTv Therapeutics VTVT

vTv Therapeutics reports $11.62 million net loss for Q3 2026

Form
10-Q
Filed
Importance
Notable
  1. Revenue: $0 for the three months ended Sep 30, 2026
  2. Net loss: $11.62 million for the three months ended Sep 30, 2026
  3. Cash and equivalents: $77.16 million at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when vTv Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What changed since last quarter

No new risk factors or legal mentions.

Compared with the 10-Q for the period ended Jun 30, 2026.

Key numbers from the XBRL in this filing and the previous one.
This filingPreviousChange vs prior 10-Q
Revenue$0$0—
Operating income and margin−$12.43M−$13.93M+11%
Net income−$11.62M−$13.05M+11%
Operating cash flow−$10.19M−$11.44M+11%
Cash$77.16M$86.64M−11%

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Ovid Therapeutics OVID public float $22M, Jun 30, 2025
  2. Marimed MRMD public float $23M, Jun 30, 2025
  3. Aptose Biosciences APTOF public float $22M, Jun 28, 2025
  4. Dare Bioscience DARE public float $21M, Jun 30, 2025
  5. Lunai Bioworks LNAI public float $21M, Dec 31, 2025

Data on this page was fetched . The filing on SEC.gov is the record.